SCHEMBL13429232

SCHEMBL13429232

O=c1cc(Oc2cccc(-c3ccc(N4CCOCC4)cc3)c2)c2ccccc2[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 4/20 0.47
LMNA P02545 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 2/20 0.42
MEN1 O00255 2/20 0.42
HPGD P15428 2/20 0.42
KMT2A Q03164 2/20 0.42
HSD17B10 Q99714 2/20 0.42
MAPT P10636 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
XDH P47989 1/20 0.42
PIK3CG P48736 1/20 0.41
EPHX1 P07099 1/20 0.41
PDGFRB P09619 2/20 0.41
FGFR1 P11362 1/20 0.41
FLT1 P17948 1/20 0.41
KDR P35968 1/20 0.41
BMPR1B O00238 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13429255 0.90 ALDH1A1 (0.46) KIF11LMNASMN1; SMN2ALDH1A1KDM4E
SCHEMBL13429235 0.87 CNR2 (0.51) MAPT
SCHEMBL13429161 0.83 HPGD (0.54) LMNASMN1; SMN2ALDH1A1KDM4EMEN1
SCHEMBL13429239 0.83 KDM4E (0.53) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL13429236 0.81 ALK (0.49) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL3221527 0.81 KIF11 (0.54) KIF11LMNASMN1; SMN2ALDH1A1KDM4E
SCHEMBL3215819 0.80 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1KDM4EMEN1HPGD
SCHEMBL3225063 0.78 ABL1 (0.44) KMT2APIK3CGPDGFRBFGFR1KDR
SCHEMBL7933316 0.78 CNR1 (0.47) LMNASMN1; SMN2ALDH1A1KDM4EHPGD
SCHEMBL13429184 0.78 GRIN2D (0.45) SMN1; SMN2ALDH1A1KDM4EHPGDEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS MTOR, RICTOR, PIK3CA KIF11 2758/4885LMNA 4098/4885SMN1; SMN2 4072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.